154 related articles for article (PubMed ID: 18992637)
21. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619
[TBL] [Abstract][Full Text] [Related]
22. Identification of promoter region methylation patterns of MGMT, CDKN2A, GSTP1, and THBS1 genes in intracranial meningioma patients.
Aydemir F; Yurtcu E; Balci TB; Sahin FI; Gulsen S; Altinors N
Genet Test Mol Biomarkers; 2012 May; 16(5):335-40. PubMed ID: 22288845
[TBL] [Abstract][Full Text] [Related]
23. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.
van Thuijl HF; Mazor T; Johnson BE; Fouse SD; Aihara K; Hong C; Malmström A; Hallbeck M; Heimans JJ; Kloezeman JJ; Stenmark-Askmalm M; Lamfers ML; Saito N; Aburatani H; Mukasa A; Berger MS; Söderkvist P; Taylor BS; Molinaro AM; Wesseling P; Reijneveld JC; Chang SM; Ylstra B; Costello JF
Acta Neuropathol; 2015 Apr; 129(4):597-607. PubMed ID: 25724300
[TBL] [Abstract][Full Text] [Related]
24. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.
Amatu A; Sartore-Bianchi A; Moutinho C; Belotti A; Bencardino K; Chirico G; Cassingena A; Rusconi F; Esposito A; Nichelatti M; Esteller M; Siena S
Clin Cancer Res; 2013 Apr; 19(8):2265-72. PubMed ID: 23422094
[TBL] [Abstract][Full Text] [Related]
25. MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.
Hassel JC; Sucker A; Edler L; Kurzen H; Moll I; Stresemann C; Spieth K; Mauch C; Rass K; Dummer R; Schadendorf D
Br J Cancer; 2010 Sep; 103(6):820-6. PubMed ID: 20736948
[TBL] [Abstract][Full Text] [Related]
26. MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.
Mathur R; Zhang Y; Grimmer MR; Hong C; Zhang M; Bollam S; Petrecca K; Clarke J; Berger MS; Phillips JJ; Oberheim-Bush NA; Molinaro AM; Chang SM; Costello JF
Neuro Oncol; 2020 Nov; 22(11):1580-1590. PubMed ID: 32166314
[TBL] [Abstract][Full Text] [Related]
27. Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
Pietrantonio F; Perrone F; de Braud F; Castano A; Maggi C; Bossi I; Gevorgyan A; Biondani P; Pacifici M; Busico A; Gariboldi M; Festinese F; Tamborini E; Di Bartolomeo M
Ann Oncol; 2014 Feb; 25(2):404-8. PubMed ID: 24379162
[TBL] [Abstract][Full Text] [Related]
28. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
[TBL] [Abstract][Full Text] [Related]
29. A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Calegari MA; Inno A; Monterisi S; Orlandi A; Santini D; Basso M; Cassano A; Martini M; Cenci T; de Pascalis I; Camarda F; Barbaro B; Larocca LM; Gori S; Tonini G; Barone C
Br J Cancer; 2017 May; 116(10):1279-1286. PubMed ID: 28427088
[TBL] [Abstract][Full Text] [Related]
30. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
Weiler M; Hartmann C; Wiewrodt D; Herrlinger U; Gorlia T; Bähr O; Meyermann R; Bamberg M; Tatagiba M; von Deimling A; Weller M; Wick W
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):670-6. PubMed ID: 19836157
[TBL] [Abstract][Full Text] [Related]
31. Case of primary diffuse leptomeningeal gliomatosis.
Yamasaki K; Yokogami K; Ohta H; Yamashita S; Uehara H; Sato Y; Takeshima H
Brain Tumor Pathol; 2014 Jul; 31(3):177-81. PubMed ID: 24473978
[TBL] [Abstract][Full Text] [Related]
32. Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors.
Ingold B; Schraml P; Heppner FL; Moch H
PLoS One; 2009; 4(3):e4775. PubMed ID: 19274096
[TBL] [Abstract][Full Text] [Related]
33. Assessment of MGMT promoter methylation status in pleomorphic xanthoastrocytoma.
Marucci G; Morandi L
J Neurooncol; 2011 Nov; 105(2):397-400. PubMed ID: 21626073
[TBL] [Abstract][Full Text] [Related]
34. Prime time for molecular marker diagnostics in neuro-oncology.
Weller M; Stupp R
Curr Opin Neurol; 2012 Dec; 25(6):743-4. PubMed ID: 23041956
[No Abstract] [Full Text] [Related]
35. How I treat glioblastoma in older patients.
Mohile NA
J Geriatr Oncol; 2016 Jan; 7(1):1-6. PubMed ID: 26725536
[TBL] [Abstract][Full Text] [Related]
36. A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.
Beasley GM; Speicher P; Augustine CK; Dolber PC; Peterson BL; Sharma K; Mosca PJ; Royal R; Ross M; Zager JS; Tyler DS
Ann Surg Oncol; 2015 Jan; 22(1):287-94. PubMed ID: 25145500
[TBL] [Abstract][Full Text] [Related]
37. Combined inhibition of vascular endothelial growth factor receptor signaling with temozolomide enhances cytotoxicity against human glioblastoma cells via downregulation of Neuropilin-1.
Lee J; Kim E; Ryu SW; Choi C; Choi K
J Neurooncol; 2016 May; 128(1):29-34. PubMed ID: 26951556
[TBL] [Abstract][Full Text] [Related]
38. DNA methylation analysis of benign and atypical meningiomas: correlation between RUNX3 methylation and WHO grade.
Majchrzak-Celińska A; Paluszczak J; Szalata M; Barciszewska AM; Nowak S; Baer-Dubowska W
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1593-601. PubMed ID: 25648363
[TBL] [Abstract][Full Text] [Related]
39. Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide.
Batisse M; Raverot G; Maqdasy S; Durando X; Sturm N; Montoriol PF; Kemeny JL; Chazal J; Trouillas J; Tauveron I
Cancer Invest; 2013 Mar; 31(3):190-6. PubMed ID: 23477586
[TBL] [Abstract][Full Text] [Related]
40. Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma with Low MGMT Protein Expression.
Komori K; Yanagisawa R; Miyairi Y; Sakashita K; Shiohara M; Fujihara I; Morita D; Nakamura T; Ogiso Y; Sano K; Shirahata M; Fukuoka K; Ichimura K; Shigeta H
Pediatr Blood Cancer; 2016 Jan; 63(1):152-5. PubMed ID: 26305586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]